Although targeting EGFR using cetuximab has shown some benefits for HPV-negative tumours, the outcome of EGFR inhibition for HPV-positive HNSCC was the opposite causing a clear inferior response and poorer survival outcome as compared with standard treatment modalities. This evidence concerns the gene EGFR and neoplasm.